Brenus Pharma raised $25M in a Series A funding round led by Angelor to accelerate clinical trials for its precision cancer vaccines.
Amount Raised
$25 Million
Round Type
Series A
LyonBiotechnologyHealth CareTherapeuticsInvestors
Description
Brenus Pharma, a biotech company developing cancer vaccines, has completed a $25 million Series A financing round. This funding will fully support the first-in-human proof-of-concept for its STC-1010 cancer vaccine.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Brenus Pharma that raised within 45 days of this round, from Fundz verified event records.
- Blue Earth Therapeutics raised $77M (Series A) on October 31, 2024.
- Archon Biosciences raised $20M (Seed) on October 30, 2024.
- Tempero Bio raised $77M on October 30, 2024.
- SynOx Therapeutics raised $92M (Series B) on October 30, 2024.
- Pathos AI raised $62M (Series C) on October 29, 2024.
- CrossBridge Bio raised $11M on October 29, 2024.
Who to call at Brenus Pharma, and when
A new round usually means Brenus Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Brenus Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Brenus Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Brenus Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Brenus Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansBrenus Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.